| Literature DB >> 24666820 |
Oxana Gavrilyuk1, Tonje Braaten, Guri Skeie, Elisabete Weiderpass, Vanessa Dumeaux, Eiliv Lund.
Abstract
BACKGROUND: Coffee and its compounds have been proposed to inhibit endometrial carcinogenesis. Studies in the Norwegian population can be especially interesting due to the high coffee consumption and increasing incidence of endometrial cancer in the country.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24666820 PMCID: PMC3986939 DOI: 10.1186/1472-6874-14-48
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Distribution of NOWAC postmenopausal participants according to consumption of total, filtered, boiled and instant coffee
| | |||||||
|---|---|---|---|---|---|---|---|
| No of participants | n = 97 926 | n = 93 858 | n = 32 049 | n = 93 858 | n = 60 025 | n = 93 858 | n = 22 501 |
| ≤ 1 cups per day | 16.1 | 80.0 | 54.4 | 40.1 | 25.6 | 91.7 | 77.5 |
| 2-3 cups per day | 32.9 | 7.9 | 16.1 | 25.9 | 30.4 | 5.4 | 13.3 |
| 4-7 cups per day | 37.8 | 8.4 | 20.2 | 25.9 | 33.4 | 2.4 | 7.5 |
| ≥ 8 cups per day | 13.2 | 3.7 | 9.3 | 8.1 | 10.6 | 0.5 | 1.7 |
| No of cases | n = 462 | n = 452 | n = 174 | n = 452 | n = 322 | n = 452 | n = 112 |
| ≤ 1 cups per day | 17.7 | 77.9 | 51.2 | 44.2 | 27.6 | 92.7 | 79.5 |
| 2-3 cups per day | 37.1 | 10.4 | 21.8 | 27.0 | 34.2 | 4.6 | 10.7 |
| 4-7 cups per day | 38.3 | 10.2 | 23.0 | 25.0 | 32.9 | 2.3 | 8.0 |
| ≥ 8 cups per day | 6.9 | 1.5 | 4.0 | 3.8 | 5.3 | 0.4 | 1.8 |
aTotal coffee is combination of responses on total coffee consumption in the total coffee version of the questionnaire and filtered, boiled and instant coffee consumption in the brewing methods version of the questionnaire. bCombined with other types: those women who positively responded to question about “total coffee consumption” or/and other brewing method (filtered, boiled, instant).
Baseline characteristics of postmenopausal NOWAC Study participants according to total coffee consumption
| Number of women (%) | 15795 (16.1) | 32200 (32.9) | 36992 (37.8) | 12939 (13.2) |
| Number of EC cases (%) | 82 (17.7) | 171 (37.1) | 177 (37.8) | 32 (6.9) |
| Mean (sd) | ||||
| Age at enrollment, years | 47.5 (8.64) | 48,7 (8.73) | 47.9 (8.31) | 43.7 (6.82) |
| Age at menarche, years | 13.4 (1.45) | 13.4 (1.37) | 13.3 (1.36) | 13.2 (1.39) |
| Age at first birth, years | 24.8 (4.53) | 24.4 (4.39) | 23.6 (4.17) | 22.7 (3.99) |
| Age at menopause, years | 48.1 (5.03) | 48.7 (8.74) | 48.3 (4.66) | 46.9 (4.95) |
| Duration of OC use, years | 2.9 (4.56) | 2.6 (4.29) | 2.5 (4.12) | 2.6 (4.01) |
| Number of children, % | ||||
| 0 | 11.4 | 9.5 | 7.9 | 7.5 |
| 1-2 | 55.4 | 53.9 | 52.6 | 53.5 |
| ≥ 3 | 33.2 | 36.6 | 39.5 | 39.0 |
| Years of total education, % | ||||
| < 9 | 16.6 | 21.2 | 28.9 | 36.7 |
| 10-12 | 30.2 | 33.3 | 36.3 | 38.3 |
| 13-16 | 32.5 | 29.9 | 24.3 | 19.3 |
| > 17 | 20.8 | 15.6 | 10.5 | 5.9 |
| Smoking status, % | ||||
| Current | 17.7 | 21.8 | 39.3 | 61.8 |
| Former | 31.1 | 35.6 | 31.9 | 24.6 |
| Never | 51.2 | 42.6 | 28.8 | 13.7 |
| BMI, % | ||||
| < 20 | 10.1 | 8.1 | 7.9 | 10.9 |
| 20-24.9 | 56.8 | 58.1 | 56.7 | 57.6 |
| 25-29.9 | 24.3 | 26.7 | 28.3 | 24.8 |
| ≥ 30 | 8.8 | 7.1 | 7.0 | 6.8 |
| HRT use, % | ||||
| Never | 79.7 | 79.9 | 83.3 | 91.1 |
| Former | 8.7 | 8.4 | 7.1 | 3.3 |
| Current | 11.6 | 11.7 | 9.7 | 5.6 |
| Prevalence of diabetes, % | 0.98 | 0.82 | 0.92 | 0.98 |
Abbreviations: NOWAC Norwegian Women and Cancer, EC Endometrial cancer, SD Standard deviation, OC Oral contraceptives, BMI Body mass index, HRT Hormone replacement therapy.
N = 97 926.
HRs and 95% CIs of endometrial cancer related to total, filtered and boiled coffee among 97 926 postmenopausal NOWAC Study participants
| Age-adjusted HR, CI 95%c | |||||
| ≤ 1 cups/day | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 2-3 cups/day | 0.87 (0.67-1.13) | 1.12 (0.83-1.53) | 1.03 (0.70-1.51) | 0.98 (0.79-1.23) | 0.93 (0.70-1.23) |
| 4-7 cups/day | 0.76 (0.59-0.99) | 1.06 (0.78-1.44) | 0.87 (0.59-1.26) | 0.89 (0.71-1.13) | 0.79 (0.60-1.06) |
| ≥ 8 cups/day | 0.44 (0.29-0.67) | 0.43 (0.2-0.91) | 0.42 (0.19-0.91) | 0.48 (0.29-0.79) | 0.45 (0.26-0.75) |
| p for trend | < 0.0001 | 0.21 | 0.02 | 0.002 | 0.03 |
| Multivariate-adjusted HR, CI 95%d | |||||
| ≤ 1 cups/day | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 2-3 cups/day | 0.91 (0.70-1.19) | 1.08 (0.79-1.46) | 1.04 (0.71-1.54) | 0.99 (0.79-1.24) | 0.99 (0.75-1.31) |
| 4-7 cups/day | 0.84 (0.65-1.1) | 1.10 (0.81-1.50) | 0.92 (0.62-1.36) | 0.95(0.76-1.20) | 0.91 (0.68-1.21) |
| ≥ 8 cups/day | 0.52 (0.34-0.79) | 0.48 (0.23-1.03) | 0.45 (0.21-1.01) | 0.55 (0.33-0.91) | 0.55 (0.32-0.94) |
| p for trend | 0.003 | 0.36 | 0.07 | 0.12 | 0.07 |
aTotal coffee is combination of responses on total coffee consumption in the total coffee version of the questionnaire and filtered, boiled and instant coffee consumption in the brewing methods version of the questionnaire. bCombined with other types: those women who positively responded to question about “total coffee consumption” or/and other brewing method (filtered, boiled, instant). cBasic model that was adjusted for age. dMultivariate model that was adjusted for parity, smoking status, BMI, duration of OC and HRT use. Abbreviations: HR Hazard ratio, CI Confidence interval, NOWAC Norwegian Women and Cancer, BMI Body mass index, OC Oral contraceptives, HRT Hormone replacement therapy.
HRs and 95% CIs of total, boiled and filtered coffee consumption stratified by BMI and smoking status in 97 926 postmenopausal NOWAC Study participants
| | |||||||
|---|---|---|---|---|---|---|---|
| BMI < 25 | ≤ 1 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| | 2-3 | 0.93 (0.63-1.38) | 0.88 (0.53-1.47) | 1.29 (0.93-1.79) | 0.96 (0.65-1.42) | 0.87 (0.52-1.46) | 1.25 (0.90-1.74) |
| | 4-7 | 0.78 (0.53-1.16) | 0.88 (0.53-1.44) | 1.05 (0.75-1.49) | 0.86 (0.58-1.29) | 0.97 (0.59-1.60) | 1.11 (0.78-1.57) |
| | ≥ 8 | 0.54 (0.31-0.96) | 0.50 (0.19-1.36) | 0.57 (0.29-1.14) | 0.65 (0.36-1.17) | 0.59 (0.22-1.63) | 0.66 (0.33-1.32) |
| p for trend | | 0.009 | 0.13 | 0.39 | 0.008 | 0.31 | 0.77 |
| BMI ≥ 25 | ≤ 1 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| | 2-3 | 0.82 (0.57-1.17) | 1.26 (0.85-1.85) | 0.79 (0.58-1.09) | 0.83 (0.58-1.19) | 1.22 (0.83-1.80) | 0.78 (0.57-1.08) |
| | 4-7 | 0.72 (0.51-1.02) | 1.13 (0.77-1.67) | 0.72 (0.51-1.02) | 0.78 (0.55-1.12) | 1.21 (0.82-1.79) | 0.83 (0.60-1.13) |
| | ≥ 8 | 0.33 (0.18-0.61) | 0.33 (0.10-1.02) | 0.40 (0.19-0.83) | 0.39 (0.21-0.73) | 0.39 (0.12-1.23) | 0.46 (0.22-0.96) |
| p for trend | | 0.0005 | 0.44 | 0.01 | 0.009 | 0.79 | 0.05 |
| Never smokers | ≤ 1 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| | 2-3 | 1.01 (0.7-1.44) | 1.09 (0.72-1.67) | 1.15 (0.85-1.57) | 1.05 (0.74-1.51) | 1.07 (0.70-1.62) | 1.19 (0.87-1.62) |
| | 4-7 | 0.97 (0.67-1.41) | 0.95 (0.57-1.58) | 0.08 (0.76-1.53) | 0.97 (0.67-1.42) | 0.91 (0.55-1.53) | 1.08 (0.76-1.53) |
| | ≥ 8 | 0.54 (0.23-1.26) | 0.36 (0.05-2.52) | 0.67 (0.25-1.83) | 0.49 (0.21-1.16) | 0.33 (0.05-2.33) | 0.63 (0.23-1.72) |
| p for trend | | 0.41 | 0.59 | 0.99 | 0.26 | 0.44 | 0.94 |
| Former smokers | ≤ 1 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| | 2-3 | 0.75 (0.47-1.19) | 1.05 (0.59-1.86) | 0.69 (0.45-1.05) | 0.76 (0.47-1.21) | 1.04 (0.58-1.85) | 0.70 (0.46-1.07) |
| | 4-7 | 0.76 (0.48-1.21) | 1.79 (1.12-2.85) | 0.79 (0.52-1.18) | 0.74 (0.46-1.18) | 1.69 (1.06-2.72) | 0.77 (0.51-1.16) |
| | ≥ 8 | 0.59 (0.29-1.20) | 0.25 (0.03-1.76) | 0.66 (0.30-1.45) | 0.57 (0.28-1.15) | 0.23 (0.03-1.67) | 0.64 (0.29-1.42) |
| p for trend | | 0.09 | 0.67 | 0.19 | 0.06 | 0.83 | 0.18 |
| Current smokers | ≤ 1 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| | 2-3 | 0.73 (0.37-1.45) | 1.16 (0.56-2.41) | 1.04 (0.60-1.78) | 0.76 (0.38-1.52) | 1.16 (0.56-2.42) | 1.04 (0.60-1.79) |
| | 4-7 | 0.61 (0.32-1.15) | 0.76 (0.39-1.48) | 0.93 (0.58-1.50) | 0.64 (0.34-1.21) | 0.77 (0.39-1.50) | 0.96 (0.59-1.55) |
| | ≥ 8 | 0.36 (0.17-0.79) | 0.69 (0.28-1.73) | 0.40 (0.17-0.95) | 0.37 (0.17-0.81) | 0.69 (0.28-1.73) | 0.40 (0.17-0.95) |
| p for trend | 0.009 | 0.30 | 0.12 | 0.01 | 0.30 | 0.13 | |
aBasic model that was adjusted for age. bMultivariate model that was adjusted for parity, smoking status, BMI, duration of OC and HRT use. Abbreviations: HR Hazard ratio, CI Confidence interval, BMI Body mass index, NOWAC Norwegian Women and Cancer, OC Oral contraceptives, HRT Hormone replacement therapy.